ULURU INC.
ULURU INC. (ULU): 4 pipeline candidates · ~27 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.3 months
D/E 0.63 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for ULURU INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.8M
Quarterly Burn
$333K
Runway
27.3 mo
Revenue
$85K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in ULURU INC.'s pipeline?
ULURU INC. (ULU) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ULURU INC.'s lead drug candidate?
ULURU INC.'s most advanced tracked candidate is altrazeal (Approved) for exuding acute wounds such as partial thickness burns, donor sites, non-healing surgical wounds, and trauma and for chronic wounds such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
What is ULURU INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ULURU INC. has approximately 27.3 months of cash runway.
Who is the CEO of ULURU INC.?
Beltway Drive Addison is the chief executive officer of ULURU INC. (ULU).
Get the full picture on ULURU INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.